|
1
|
Gridelli C, Maione P, Comunale D and Rossi
A: Adjuvant chemotherapy in elderly patients with non-small-cell
lung cancer. Cancer Control. 14:57–62. 2007.PubMed/NCBI
|
|
2
|
Wu SH: Effect of docetaxel with cisplatin
in treating advanced non-small cell lung cancer. J Hainan Med Coll.
16:1615–1617. 2010.In Chinese.
|
|
3
|
Li XT: Docetaxel and cisplatin treatment
of non-small cell lung cancer analysis. Chin J Mod Drug Appl.
4:34–35. 2010.
|
|
4
|
Lu XM and Mao GX: A study of docetaxel
plus cisplatin versus gemcitabine plus cisplatin in treating
advanced non-small cell lung cancer. J Basic Clin Oncol.
22:308–310. 2009.
|
|
5
|
Xu Y: Docetaxel combined with cisplatin in
the treatment of advanced non-small cell lung cancer. Chin J Mod
Drug Applic. 4:26–28. 2010.
|
|
6
|
Shao JH: Efficacy of docetaxel combined
with nedaplatin or cisplatin in patients with advanced non-small
cell lung cancer. Chin J N Drugs. 19:599–601. 2010.
|
|
7
|
Zhang CH, Ren ZH, Li M, et al: Cisplatin
plus docetaxel combination in the first-line treatment of advanced
non-small cell lung cancer. Chin J Clin Oncol Rehab. 17:54–56.
2010.
|
|
8
|
Stinchcombe TE and Socinski MA:
Considerations for second-line therapy of non-small cell lung
cancer. Oncologist. 13(Suppl 1): S28–S36. 2008. View Article : Google Scholar
|
|
9
|
Xu YZ and Xu LW: The exploration of 70
years of age or older chemotherapy against non-small cell lung
cancer cells. Zhejiang Clin Med. 9:1226–1227. 2007.In Chinese.
|
|
10
|
Li JJ: A study of cisplatin plus docetaxel
or gemcitabine in treating advanced non small cell lung cancer. Mod
Med. 18:54–55. 582011.
|
|
11
|
Xiong Y, Zhou TC, Liu Y, Wang ZW, Lin XL,
Song XL, Shi XY and Liao ZW: Clinical analysis of efficacy in
docetaxel plus cisplatin chemotherapy with 3-DCRT treating the
patients with locally advanced NSCLC. China J Cancer Prev Treat.
17:699–702. 2010.
|
|
12
|
Greco FA, Spigel DR, Burris HA III,
Shipley DL, Farley C, Gandhi J, Houston GA and Hainsworth JD:
Weekly docetaxel versus docetaxel/gemcitabine in elderly/poor
performance status (PS) patients (pts) with stage III B/IV
non-small cell lung cancer (NSCLC): Randomized phase III trial of
the Minnie Pearl Cancer Research Network. J Clin Oncol. 25(Suppl):
S75342007.
|
|
13
|
Kudoh S, Takeda K, Nakagawa K, Takada M,
Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, et al:
Randomized phase study of docetaxel versus vinorelbine for elderly
patients with advanced non-small cell lung cancer (NSCLC): Results
of a west Japan thoracic oncology group trial (WJTOG 9904). J Clin
Oncol. 24:3657–3663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Q, Li R, Zhu Z, Qian X, Guan W, Yu L,
Yang M, Jiang X and Liu B: Enhanced antitumor efficacy,
biodistribution and penetration of docetaxel-loaded biodegradable
nanoparticles. Int J Pharm. 430:350–358. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghosh SC, Neslihan Alpay S and
Klostergaard J: CD44: A validated target for improved delivery of
cancer therapeutics. Expert Opin Ther Targets. 16:635–650. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao W, Xiang B, Meng TT, Liu F and Qi XR:
Chemotherapeutic drug delivery to cancer cells using a combination
of folate targeting and tumor microenvironment-sensitive
polypeptides. Biomaterials. 34:4137–4149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang F, Zhang D, Zhang Q, Chen Y, Zheng D,
Hao L, Duan C, Jia L, Liu G and Liu Y: Synergistic effect of
folate-mediated targeting and verapamil-mediated P-gp inhibition
with paclitaxel-polymer micelles to overcome multi-drug resistance.
Biomaterials. 32:9444–9456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ganesh S, Iyer AK, Gattacceca F, Morrissey
DV and Amiji MM: In vivo biodistribution of siRNA and cisplatin
administered using CD44-targeted hyaluronic acid nanoparticles. J
Control Release. 172:699–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iyer AK, Greish K, Seki T, Okazaki S, Fang
J, Takeshita K and Maeda H: Polymeric micelles of zinc
protoporphyrin for tumor targeted delivery based on EPR effect and
singlet oxygen generation. J Drug Target. 15:496–506. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang J, Nakamura H and Maeda H: The EPR
effect: Unique features of tumor blood vessels for drug delivery,
factors involved, and limitations and augmentation of the effect.
Adv Drug Deliv Rev. 63:136–151. 2011. View Article : Google Scholar
|
|
21
|
Tang N, Du G, Wang N, Liu C, Hang H and
Liang W: Improving penetration in tumors with nanoassemblies of
phospholipids and doxorubicin. J Natl Cancer Inst. 99:1004–1015.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li RY: Docetaxel-loaded PEG-albumin
nanoparticles for anti-metastasis in murine 4T1 breast cancer.
Yanbian University PhD Thesis. 2012
|
|
23
|
Li JQ, Yang ZZ, Meng TT and Qi XR: The use
of cationic liposomes to co-deliver docetaxel and siRNA for
targeted therapy of hepatocelluar carcinoma. J Chin Pharm Sci.
23:667–673. 2014. View Article : Google Scholar
|
|
24
|
Li Y, Jin M, Shao S, Huang W, Yang F, Chen
W, Zhang S, Xia G and Gao Z: Small-sized polymeric micelles
incorporating docetaxel suppress distant metastases in the
clinically-relevant 4T1 mouse breast cancer model. BMC Cancer.
14:329–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim D, Gao ZG, Lee ES and Bae YH: In vivo
evaluation of doxorubicin-loaded polymeric micelles targeting
folate receptors and early endosomal pH in drug-resistant ovarian
cancer. Mol Pharm. 6:1353–1362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao ZG, Fain HD and Rapoport N: Controlled
and targeted tumor chemotherapy by micellar-encapsulated drug and
ultrasound. J Control Release. 102:203–222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao L, Xiong X, Sun X, Zhu Y, Yang H,
Chen H, Gan L, Xu H and Yang X: Role of cellular uptake in the
reversal of multidrug resistance by PEG-b-PLA polymeric micelles.
Biomaterials. 32:5148–5157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen W, Zhan C, Gu B, Meng Q, Wang H, Lu W
and Hou H: Targeted brain delivery of itraconazole via RVG29
anchored nanoparticles. J Drug Target. 19:228–234. 2011. View Article : Google Scholar
|
|
29
|
Mu L, Teo MM, Ning HZ, Tan CS and Feng SS:
Novel powder formulations for controlled delivery of poorly soluble
anticancer drug: Application and investigation of TPGS and PEG in
spray-dried particulate system. J Control Release. 103:565–575.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Li R, Qian X, Ding Y, Tu Y, Guo R,
Hu Y, Jiang X, Guo W and Liu B: Superior antitumor efficiency of
cisplatin-loaded nanoparticles by intratumoral delivery with
decreased tumor metabolism rate. Eur J Pharm Biopharm. 70:726–734.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jin G, Jin M, Yin X, Jin Z, Chen L and Gao
Z: A comparative study on the effect of docetaxel-albumin
nanoparticles and docetaxel-loaded PEG-albumin nanoparticles
against non-small cell lung cancer. Int J Oncol. 47:1945–1953.
2015.PubMed/NCBI
|
|
32
|
Gong C, Xie Y, Wu Q, Wang Y, Deng S, Xiong
D, Liu L, Xiang M, Qian Z and Wei Y: Improving anti-tumor activity
with polymeric micelles entrapping paclitaxel in pulmonary
carcinoma. Nanoscale. 4:6004–6017. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang F, Zhang D, Zhang Q, Guo S, Zheng D,
Hao L, Guo H and Li C: Tissue distribution and pharmacokinetics
evaluation of DOMC-FA micelles for intravenous delivery of PTX. J
Drug Target. 21:137–145. 2013. View Article : Google Scholar
|
|
34
|
Wang J, Huo MR and Zhang XY: Progress in
hyaluronic acidbased targeted nano-drug delivery systems. Chin J
Pharm. 44:828–835. 2013.
|
